Investors
Corporate Overview
NetraMark is a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI / ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and / or efficacy of treatment.
Latest Press Releases
Oct 2nd, 2024
Sept 11th, 2024
Aug 20th, 2024
Corporate Documents
Audit Committee Charter
MNP LLP
[ Auditors ]
111 Richmond St. W Suite 300 Toronto, ON M5H 2G4
416.596.1711
Odyssey Trust
[ Transfer Agent ]
United Kingdom Building 323 409 Granville Street Vancouver, BC V6C 1T2
1.833.392.7716
Corporate Directory
NetraMark
[ Head Office ]
1655 Dupont St. #Suite 101 Toronto, ON M6P 3S9
investors@netramark.com
Fasken Martineau Dumoulin LLP
[ Legal ]
2400 – 333 Bay St. Toronto, ON M5H 2T6
416.366.8381